Drug | Tablet
Sitagliptin 50 mg + Metformin hydrochloride 500 mg (as immediate-release)
Type 2 diabetes mellitus (to improve blood glucose control along with diet and exercise), especially in patients inadequately controlled on metformin alone or requiring sitagliptin + metformin combination
Sitagliptin is a DPP-4 inhibitor that increases incretin hormones, leading to increased insulin release and reduced glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production and improves insulin sensitivity, reducing intestinal glucose absorption and lowering blood glucose levels.
Tablet; take exactly as prescribed. Usually taken with meals to reduce stomach upset; swallow whole with water (do not crush/chew unless advised). Dose and frequency depend on blood sugar control and kidney function.
Common side effects of Zomelis Met 50/500 Tablet may include:
Prescription (Schedule H) medicine. Risk of lactic acidosis with metformin—seek urgent care for fast breathing, severe weakness, muscle pain, unusual sleepiness, or abdominal discomfort; higher risk in kidney impairment, dehydration, severe infection, hypoxia, heavy alcohol use, and elderly. Monitor renal function before and during therapy; not recommended in severe renal impairment. Temporarily stop around iodinated contrast procedures and major surgery as advised. Sitagliptin may rarely cause pancreatitis—seek medical help for severe persistent abdominal pain. Use caution in heart failure history and in patients prone to hypoglycaemia when combined with insulin or sulfonylureas.
